
|Articles|January 1, 2003
Injectable Silicone Shows Promisefor Treatment of HIV-associated Facial Lipoatrophy
Chicago -- Off-label experience using injectable silicone (Silikon 1000) in an investigational protocol indicates it is a highly effective and, thus far, very safe modality for treating facial lipoatrophy in HIV-infected patients, Derek H. Jones, M.D., said at the annual meeting of the American Society for Dermatologic Surgery.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5

















